Pai Du Ruan Gan Tang is the empirical formula for treatment of mid-late stage primary liver cancer in our hospital. The case selection: the patients are diagnosed as primary liver cancer via pathology or clinical examination and can live for more than 2 months, their liver functions are primarily general, the patients’ age is between 18 and 75 cases, the score for the quality of life > 60, if the patients take chemotherapy or operation, they should be the patients who have finished their chemotherapy for more than one month and have tumor or the tumor have not been removed yet. There are 70 cases that are randomly divided into simple herbal group and the group that takes systematic treatment (herbs plus interventional therapy), there are 30 cases in herbal group and 40 cases in systematic treatment group. The ingredients of Pai Du Ruan Gan Tang include Bie Jia 30g (decoct first), Chuan Bei Mu 10g, Xia Ku Cao 20g, Bai Hua She She Cao 60g, Chi Shao Yao 15g, Hai Zao 15g, Yin Chen 10g (decoct later), Pu Huang 10g (decoct with packing). As for simple herbal group: we choose Pai Du Ruan Gan Tang singly. Systematic treatment group: on the basis of hepatic artery catheter intervention chemotherapy, oral taking Xiao Zheng Pai Du Ruan Gan Tang. Intervention chemotherapy scheme: cisplatin (DDP), adriamycin (ADM), mitomycin (MMC); or carboplatin (CBP), flurouracil (5FU), MMC scheme. The treatment should last 3 months (one course), then review.
Result: observing the change of the tumor before and after treatment (CR + PR), the two groups have no obvious difference, but, from the perspective of stabilization rate of tumor (CR+PR+NC), the systematic treatment group is better than herbal group. There are no obvious differences in changing of quality of life before and after treatment in both groups. And, no evident difference in long-dated survival rate can be found in both groups, a slight advantage in survival rate can be identified in treatment group after more than 2 years.
Key words: Pai Du Ruan Gan Tang, treatment, Mid-late Primary Liver Cancer, clinical observation
Writer: Shangjian Sun, Xiude Niu, Yang Fan. Supervisor: Zhong Li
Jinhua city Ai Ke hospital, Zhejiang province (321017)
Dong Zhi Men hospital, Beijing university of Chinese medicine
Comments: